FDA Seeks Comments on Obesity and Drug Dosing in Clinical Development
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
FDA is opening a public comment docket on how obesity should be considered when studying drug dosing, safety, and effectiveness. The agency wants input on whether obesity changes how drugs move through and act in the body, and how those effects should be measured during development of drugs and biological products. Drug companies, clinical trial sponsors, researchers, clinicians, and patient groups may want to comment. The notice does not create new dosing rules or trial requirements now, but feedback could shape future FDA thinking on study design, labeling, and dose recommendations for adults and children with obesity. Comments are due by June 30, 2026.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA opens a public docket on obesity and drug dosing considerations in drug development.
- The agency asks for evidence and views on how obesity affects drug pharmacokinetics, pharmacodynamics, safety, effectiveness, and dosing recommendations.
- Comments must be submitted by June 30, 2026, and public electronic comments will be posted without changes.
Obligations
What this law requires
Submit any electronic or written comments on the FDA docket by June 30, 2026; late, untimely filed comments will not be considered.
Include Docket No. FDA-2026-N-3499 in all submissions concerning “Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments.”
Submit electronic comments through the Federal eRulemaking Portal at https://www.regulations.gov and follow the portal’s instructions for submitting comments.
Do not include confidential information in an electronic comment unless the submitter is willing for that information to be posted publicly; electronic comments and attachments will be posted unchanged on regulations.gov.
Submit written or paper comments by mail, hand delivery, or courier to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.